HT-KIT demonstrates significant tumor downregulation and over 80% reduction in KIT expression in preclinical models of GIST and systemic mastocytosis. The therapy targets KIT gene expression at the ...
(RTTNews) - Hoth Therapeutics, Inc. (HOTH), a patient-focused biopharmaceutical company developing innovative therapies for unmet medical needs, Monday announced compelling preclinical data for HT-KIT ...
HT-KIT significantly reduces tumor burden and induces cell death in preclinical GIST models by targeting KIT mutations. Rapid tumor cell death observed within 24 hours of HT-KIT treatment, with ...
HOTH ALERT: Hoth Therapeutics Reports Positive Preclinical Safety Data for HT-KIT — Dose-Dependent Activity, No Toxicity, IND on Deck HOTH announces strong preclinical data for HT-KIT showing ...
(RTTNews) - Hoth Therapeutics, Inc. (HOTH) announced combined positive findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT, including compelling anti-tumor ...
Hoth continues to advance HT-001 in its Phase 2 CLEER-001 clinical trial targeting EGFR-inhibitor–associated rash, a significant unmet need in oncology supportive care. Recent progress includes: ...
NEW YORK, March 11, 2022 /PR Newswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) designated HT ...
New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 ...
Hoth Therapeutics Inc. (NASDAQ: HOTH) on Wednesday announced the deployment of the OpenAI API to support IND-enabling development of HT-KIT, targeting rare and aggressive KIT-driven cancers. The ...
NEW YORK, June 1, 2021 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today plans to host a virtual information session on its pipeline ...
Chinese Patent Approved Covering HT-KIT Technology Designed to Induce Cancer Cell Apoptosis, Expanding Protection in One of the World's Largest Oncology Markets NEW YORK, Jan. 21, 2026 /PRNewswire/ -- ...
Hoth Therapeutics Inc (NASDAQ:HOTH) announced that HT-KIT, a new molecular entity for advance systemic mastocytosis, achieved encouraging preclinical results. The preclinical research was conducted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results